menu
    • menu
    [{"orgOrder":0,"company":"Oxular","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection, Sustained Release","sponsorNew":"Oxular \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Oxular","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection, Sustained Release","sponsorNew":"Oxular \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Forbion"},{"orgOrder":0,"company":"Oxular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OXU-003","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Oxular

    Menu

    Oxular

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Regeneron Buys London-Based Ocular Biotech

                            Details : Through the acquisition, Regeneron will leverage Ocular Biotech portfolio, which includes the OXU-001 (dexamethasone acetate) the proprietary suprachoroidal microcatheter delivery device for DME.

                            Product Name : OXU-001

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            January 02, 2025

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Forbion

                            Deal Size : $37.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Oxular Raises $37 Million

                            Details : Proceeds will fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline.

                            Product Name : OXU-001

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            January 03, 2021

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Forbion

                            Deal Size : $37.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed

                            Oxular

                            United Kingdom arrow
                            Pharmaceutical Sciences
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OXU-003

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment

                            Details : Oxular's OXU-003 programme for the treatment of retinoblastoma consists of a proprietary anti-tumour drug which utilises Oxular's formulation and ocular administration technology to safely deliver a precise amount of drug adjacent to the primary ocular t...

                            Product Name : OXU-003

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : OXU-003

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth